Literature DB >> 22215887

Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma.

S Muzahir1, M Mian, I Munir, M K Nawaz, Z S Faruqui, K A Mufti, H Bashir, N Uddin, N Siddiqui, A U R Maaz, M T Mahmood.   

Abstract

OBJECTIVE: The aim of the study was to evaluate the potential role of fludeoxyglucose (FDG)-positron emission tomography (PET)/CT in the detection of bone/bone marrow disease in patients with Hodgkin's lymphoma (HL).
METHODS: We retrospectively reviewed ((18)F)-FDG-PET/CT scans of 122 newly diagnosed, biopsy-proven cases of HL performed between November 2009 and June 2010. All the patients were staged before treatment by both PET/CT and bone marrow biopsy (BMB). Patients were subdivided into three groups based on the findings of FDG-PET/CT. Group A consisted of patients showing diffuse FDG uptake, Group B consisted of patients showing unifocal FDG uptake and Group C patients showed multifocal FDG-avid foci on PET/CT scans. Bone marrow results were also reviewed and considered positive if lymphomatous involvement was detected on bone marrow trephine biopsy. BMB results were correlated with FDG-PET/CT findings.
RESULTS: There were 122 patients in total-81 (66.4%) were male and 41 (33.6%) were female. The age range was from 6 years to 78 years (mean 35.70 years). PET/CT was reported as negative for bone/bone marrow involvement in 85 (69.7%) patients, while the remaining 37 showed abnormal FDG uptake. The sensitivity of FDG-PET/CT was calculated to be 100%, the specificity was 76.57%, the negative predictive value was 76.57%, the positive predictive value was 29.72% and the diagnostic accuracy was 78.62%.
CONCLUSION: (18)F-FDG-PET/CT and BMB are complementary in the evaluation of bone marrow disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215887      PMCID: PMC3587106          DOI: 10.1259/bjr/29583493

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  36 in total

1.  Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Authors:  K Spaepen; S Stroobants; P Dupont; J Thomas; P Vandenberghe; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

2.  Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases.

Authors:  R D Brunning; C D Bloomfield; R W McKenna; L A Peterson
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

Review 3.  CT and MR imaging in Hodgkin's disease--present and future.

Authors:  Axel Gossmann; Hans Theodor Eich; Andreas Engert; Andreas Josting; Rolf-Peter Müller; Volker Diehl; Klaus-Jürgen Lackner
Journal:  Eur J Haematol Suppl       Date:  2005-07

4.  18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

Authors:  Emilios E Pakos; Andreas D Fotopoulos; John P A Ioannidis
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

Review 5.  The role of FDG PET in the management of lymphoma: what is the evidence base?

Authors:  Anna M Kirby; N George Mikhaeel
Journal:  Nucl Med Commun       Date:  2007-05       Impact factor: 1.690

6.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

7.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

8.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.

Authors:  S Partridge; A Timothy; M J O'Doherty; S F Hain; S Rankin; G Mikhaeel
Journal:  Ann Oncol       Date:  2000-10       Impact factor: 32.976

9.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

10.  A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma.

Authors:  Alessandro Levis; Daniela Pietrasanta; Laura Godio; Umberto Vitolo; Giorgio Ciravegna; Francesco Di Vito; Paolo Gavarotti; Tommasina Guglielmelli; Lorella Orsucci; Ermanno Raviolo; Delia Rota Scalabrini; Flavia Salvi; Anna Tonso; Massimo Aglietta; Mario Boccadoro; Andrea Gallamini; Giuseppe Saglio; Enzo Scassa; Eugenio Gallo
Journal:  Clin Lymphoma       Date:  2004-06
View more
  9 in total

1.  The diagnostic value of FDG-PET cannot be judged by iliac bone marrow biopsy.

Authors:  G Cheng
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

Review 2.  Multimodality imaging of osseous involvement In haematological malignancies.

Authors:  Abhishek R Keraliya; Katherine M Krajewski; Jyothi P Jagannathan; Atul B Shinagare; Marta Braschi-Amirfarzan; Sree H Tirumani; Nikhil H Ramaiya
Journal:  Br J Radiol       Date:  2016-01-19       Impact factor: 3.039

3.  18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin's lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement.

Authors:  Aamna Hassan; Maimoona Siddique; Humayun Bashir; Saima Riaz; Rabia Wali; Asma Mahreen; M Khalid Nawaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-22       Impact factor: 9.236

4.  Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.

Authors:  Michal Weiler-Sagie; Olga Kagna; Eldad J Dann; Ayelet Ben-Barak; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

Review 5.  Current role of FDG PET/CT in lymphoma.

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-12       Impact factor: 9.236

6.  Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.

Authors:  Masaya Iwamuro; Hiroyuki Okada; Katsuyoshi Takata; Katsuji Shinagawa; Shigeatsu Fujiki; Junji Shiode; Atsushi Imagawa; Masashi Araki; Toshiaki Morito; Mamoru Nishimura; Motowo Mizuno; Tomoki Inaba; Seiyu Suzuki; Yoshinari Kawai; Tadashi Yoshino; Yoshiro Kawahara; Akinobu Takaki; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

7.  Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET-CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma.

Authors:  Mesut Göçer; Erdal Kurtoğlu
Journal:  Indian J Hematol Blood Transfus       Date:  2020-05-04       Impact factor: 0.900

8.  Efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma.

Authors:  Ali Ozan Öner; Evrim Sürer Budak; Funda Aydın; Ozan Salim; Orhan Kemal Yücel; Bahar Akkaya; Tayfur Toptaş; Adil Boz; Akın Yıldız; Fırat Güngör; Levent Undar
Journal:  Mol Imaging Radionucl Ther       Date:  2017-06-01

9.  The Correlation Between Pre-treatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters and Clinical Prognostic Factors in Pediatric Hodgkin Lymphoma.

Authors:  Ebru Tatcı; İnci Uslu Biner; Suna Emir; Hikmet Gülşah Tanyıldız; Özlem Özmen; Engin Alagöz; Atila Gökçek; Gürses Şahin
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.